| Symbol | KYTX |
|---|---|
| Name | KYVERNA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 5980 HORTON STREET,SUITE 550, EMERYVILLE, California, United States |
| Telephone | +1 (510) 626-8331 |
| Fax | — |
| — | |
| Website | https://www.kyvernatx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001994702 |
| Description | Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyvernas pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Kyverna Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-350332 <b>Size:</b> 8 KB
Read more(30% Negative) KYVERNA THERAPEUTICS, INC. (KYTX) Reports Q3 2026 Financial Results
Read moreKyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
Read more(75% Positive) KYVERNA THERAPEUTICS, INC. (KYTX) Provides Update on agreement for both U
Read moreKyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
Read moreKyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
Read moreKyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
Read more(99% Neutral) KYVERNA THERAPEUTICS, INC. (KYTX) Announces Regulatory Update
Read moreMartini Gregory S. 🟢 acquired 325.0K shares (1 derivative) of Kyverna Therapeutics, Inc. (KYTX) at $8.54 ($2.8M) Transaction Date: May 18, 2026 | Filing ID: 232681
Read moreNew Form 3 - Kyverna Therapeutics, Inc. <b>Filed:</b> 2026-05-20 <b>AccNo:</b> 0001193125-26-232683 <b>Size:</b> 13 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07403188 | A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101 | — | Refractory Lupus Nephritis | Recruiting | 2025-11-24 | 2041-01-01 | ClinicalTrials.gov |
| NCT06475495 | Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Pat… | Phase1 | Rheumatoid Arthritis | Active_Not_Recruiting | 2024-12-04 | 2027-06-01 | ClinicalTrials.gov |
| NCT06588491 | KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Ther… | Phase2 | Stiff-Person Syndrome | Completed | 2024-09-25 | 2026-06-25 | ClinicalTrials.gov |
| NCT06384976 | KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Pr… | Phase2 | Multiple Sclerosis, Primary Progressive | Active_Not_Recruiting | 2024-09-20 | 2029-01-01 | ClinicalTrials.gov |
| NCT06193889 | KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patie… | Phase2 | Myasthenia Gravis | Recruiting | 2024-08-28 | 2028-09-01 | ClinicalTrials.gov |
| NCT06400303 | KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Ther… | Phase1 | Systemic Sclerosis | Active_Not_Recruiting | 2024-08-06 | 2027-03-01 | ClinicalTrials.gov |
| NCT06451159 | A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment R… | Phase1 | Progressive Multiple Sclerosis | Active_Not_Recruiting | 2024-06-20 | 2027-02-01 | ClinicalTrials.gov |
| NCT06138132 | A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subje… | Phase1 | Multiple Sclerosis | Recruiting | 2024-04-10 | 2027-06-01 | ClinicalTrials.gov |
| NCT05938725 | KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Ther… | Phase1 | Lupus Nephritis | Active_Not_Recruiting | 2023-04-28 | 2027-08-01 | ClinicalTrials.gov |
| NCT06342960 | KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Ther… | Phase1 | Lupus Nephritis | Active_Not_Recruiting | 2022-12-01 | 2029-01-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Chemotherapy: fludarabine (FLU) | Drug | Phase PHASE1 | Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT06451159 |
| Chemotherapy: cyclophosphamide (CYC) | Drug | Phase PHASE1 | Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT06451159 |
| KYV-101 (Biological) - 1 ×10^8 cells | Other | Phase PHASE1 | Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT06451159 |
| KYV-101 (Biological) - 0.33 ×10^8 cells | Other | Phase PHASE1 | Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT06451159 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Stiff-Person Syndrome | COMPLETED | NCT06588491 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Anti-CD20 mAB | Other | Phase PHASE2 | Multiple Sclerosis, Primary Progressive | ACTIVE_NOT_RECRUITING | NCT06384976 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Multiple Sclerosis, Primary Progressive | ACTIVE_NOT_RECRUITING | NCT06384976 |
| KYV-101 | Other | Phase PHASE2 | Multiple Sclerosis, Primary Progressive | ACTIVE_NOT_RECRUITING | NCT06384976 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Stiff-Person Syndrome | ACTIVE_NOT_RECRUITING | NCT06588491 |
| KYV-101 | Other | Preclinical | Refractory Lupus Nephritis | RECRUITING | NCT07403188 |
| Standard lymphodepletion regimen | Other | Phase PHASE1 | Systemic Sclerosis | ACTIVE_NOT_RECRUITING | NCT06400303 |
| KYV-101 | Other | Phase PHASE1 | Systemic Sclerosis | ACTIVE_NOT_RECRUITING | NCT06400303 |
| Standard lymphodepletion regimen | Other | Phase PHASE1 | Lupus Nephritis | ACTIVE_NOT_RECRUITING | NCT06342960 |
| KYV-101 anti-CD19 CAR-T cell therapy | Drug | Phase PHASE1 | Lupus Nephritis | ACTIVE_NOT_RECRUITING | NCT06342960 |
| Standard lymphodepletion regimen | Other | Phase PHASE1 | Lupus Nephritis | ACTIVE_NOT_RECRUITING | NCT05938725 |
| KYV-101 anti-CD19 CAR-T cell therapy | Drug | Phase PHASE1 | Lupus Nephritis | ACTIVE_NOT_RECRUITING | NCT05938725 |
| Chemotherapy: fludarabine (FLU) | Drug | Phase PHASE1 | Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT06451159 |
| Chemotherapy: cyclophosphamide (CYC) | Drug | Phase PHASE1 | Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT06451159 |
| KYV-101 (Biological) - 1 ×10^8 cells | Other | Phase PHASE1 | Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT06451159 |
| KYV-101 (Biological) - 0.33 ×10^8 cells | Other | Phase PHASE1 | Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT06451159 |
| Standard lymphodepletion regimen | Other | Phase PHASE1 | Multiple Sclerosis | RECRUITING | NCT06138132 |
| KYV-101 anti-CD19 CAR-T cell therapy | Drug | Phase PHASE1 | Multiple Sclerosis | RECRUITING | NCT06138132 |
| Rituximab (active comparator) | Other | Phase PHASE1 | Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING | NCT06475495 |
| KYV101 | Other | Phase PHASE1 | Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING | NCT06475495 |
| KYV-101 | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard lymphodepletion regimen | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |
| Standard of Care Treatment | Drug | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT06193889 |